| Literature DB >> 21232094 |
Lars Englberger1, Rakesh M Suri, Zhuo Li, Edward T Casey, Richard C Daly, Joseph A Dearani, Hartzell V Schaff.
Abstract
INTRODUCTION: The RIFLE (risk, injury, failure, loss of kidney function, and end-stage renal failure) classification for acute kidney injury (AKI) was recently modified by the Acute Kidney Injury Network (AKIN). The two definition systems differ in several aspects, and it is not clearly determined which has the better clinical accuracy.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21232094 PMCID: PMC3222049 DOI: 10.1186/cc9960
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Description of RIFLE [1] and AKIN [2] definition criteria for AKI used in analysis
| Definition System | AKI | ||
|---|---|---|---|
| Seven-day interval | sCr ≥1.5-fold increase or eGFR >25% decrease compared to baseline | sCr ≥2-fold increase or eGFR >50% decrease compared to baseline | sCr ≥3-fold increase or eGFR >75% decrease compared to baseline, or sCr increase to ≥4 mg/dL in setting of an increase of ≥0.5 mg/dL |
| 48-hour moving window | sCr ≥1.5-fold increase or ≥ 0.3 mg/dL | sCr ≥2-fold increase | sCr ≥3-fold increase compared to baseline, or sCr increase to ≥4 mg/dL in setting of an increase of ≥0.5 mg/dL, or RRT |
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; sCr, serum creatinine.
Patient cohort characteristics
| Entire cohort | |
|---|---|
| ( | |
| Demographics | |
| Age, years | 64.4 ± 14.2 |
| Female sex, n (%) | 1,633 (34) |
| Medical history | |
| Diabetes, n (%) | 981 (20) |
| Hypertension, n (%) | 3,246 (67) |
| Chronic lung disease, n (%) | 293 (13) |
| Extracardiac arteriopathy, n (%) | 985 (20) |
| History of renal failure, n (%) | 172 (4) |
| Baseline renal function | |
| Baseline serum creatinine, mg/dL | 1.13 ± 0.29 |
| Patients with baseline serum creatinine >2.0 mg/dL, n (%) | 63 (1) |
| Baseline eGFR, mL/min/1.73 m | 68 ± 19 |
| Baseline eGFR >60 mL/min/1.73 m | 3,181 (66) |
| Baseline eGFR 31 to 60 mL/min/1.73 m | 1,596 (33) |
| Baseline eGFR ≤30 mL/min/1.73 m | 50 (1) |
| Preoperative cardiac status | |
| Prior cardiac surgery, n (%) | 721 (15) |
| LVEF >60%, n (%) | 2,405 (50) |
| LVEF 41-60%, n (%) | 1,655 (34) |
| LVEF 21-40, n (%) | 442 (9) |
| LVEF ≤20%, n (%) | 55 (1) |
| LVEF (missing value), n (%) | 279 (6) |
| History of Myocardial infarction, n (%) | 1,027 (21) |
| Congestive heart failure, n (%) | 775 (16) |
| NYHA functional class IV, n (%) | 913 (19) |
| Cardiogenic shock, n (%) | 34 (1) |
| Preoperative IABP, n (%) | 77 (2) |
| Preop on inotropes, n (%) | 114 (2) |
| Operative details | |
| CABG only, n (%) | 1,258 (26) |
| CABG & Valve only, n (%) | 566 (12) |
| Valve surgery, n (%) | 1,196 (25) |
| Other/Combined surgery, n (%) | 1,816 (37) |
| Elective surgery, (%) | 3,947 (82) |
| Urgent surgery, n (%) | 811 (17) |
| Emergent surgery & rescue, n (%) | 78 (2) |
| CPB duration, minutes | 85 ± 48 |
| Cross-clamp time, minutes | 58 ± 32 |
| Patients with circulatory arrest, n (%) | 220 (5) |
| Outcomes | |
| Intra/postop IABP, n (%) | 173 (4) |
| Intra/Postop ECMO or VAD, n (%) | 20 (0.4) |
| Revision for bleeding, n (%) | 192 (4) |
| Operative mortality, n (%) | 89 (1.8) |
| Hospital length of stay (alive), days | 6 (5 to 8) |
Data are mean ± SD and median (interquartile range) unless otherwise specified.
CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; IABP, intra-aortic ballon pump; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VAD, ventricular assist device.
Agreement of RIFLE and AKIN definitions (numbers of patients and percentage of entire study cohort)
| Definitions |
| |||||
|---|---|---|---|---|---|---|
| no-AKI | stage 1 | stage 2 | stage 3 | |||
| no-AKI | 466 | 0 | 3 | 3,921 | ||
| (9.6%) | (0.06%) | (81.1%) | ||||
| class R | 112 | 5 | 16 | 715 | ||
| (2.3%) | (0.1%) | (0.33%) | (14.8%) | |||
| class I | 0 | 92 | 27 | 169 | ||
| (1.9%) | (0.56%) | (3.5%) | ||||
| class F | 0 | 1 | 2 | 31 | ||
| (0.02%) | (0.04%) | (0.64%) | ||||
| 3,564 | 1,141 | 57 | 74 | |||
| (73.7%) | (23.6%) | (1.2%) | (1.5%) | |||
Outcomes by RIFLE and AKIN
| RIFLE stage | No-AKI | class R | class I | class F |
|
|---|---|---|---|---|---|
| n (%) | 3,921 (81.1) | 715 (14.8) | 169 (3.5) | 31 (0.64) | |
| RRT, n (%) | 8 (0.2) | 33 (4.6) | 37 (21.9) | 18 (58.1) | <0.001 |
| Mortality, n (%) | 25 (0.64) | 27 (3.8) | 31 (18.3) | 6 (19.4) | <0.001 |
| Prolonged intubation (alive), n (%) | 248 (6.4) | 140 (20.3) | 57 (41.3) | 15 (60.0) | <0.001 |
| ICU length of stay (alive), hours | 25 (21 to 45) | 46 (23 to 93) | 105 (53 to 192) | 188 (77 to 323) | <0.001 |
| Hospital length of stay (alive), days | 6 (5 to 7) | 8 (6 to 11) | 11 (8 to 21) | 18 (10 to 27) | <0.001 |
| n (%) | 3,564 (73.7) | 1,141 (23.6) | 57 (1.2) | 74 (1.5) | |
| RRT, n (%) | 4 (0.1) | 24 (2.1) | 5 (8.8) | 63 (85.1) | <0.001 |
| Mortality, n (%) | 19 (0.53) | 30 (2.6) | 7 (12.3) | 33 (44.6) | <0.001 |
| Prolonged intubation (alive), n (%) | 211 (6.0) | 204 (18.4) | 17 (34.0) | 28 (68.3) | <0.001 |
| ICU length of stay (alive), hours | 25 (22 to 44) | 44 (22 to 90) | 72 (29 to 147) | 210 (120 to 356) | <0.001 |
| Hospital length of stay (alive), days | 6 (5 to 7) | 7 (6 to 10) | 10 (7 to 14) | 19 (13 to 27) | <0.001 |
Data are presented as median (interquartile range) if not otherwise stated.
RRT, renal replacement therapy.
Predictive ability of RIFLE and AKIN for outcome variables by logistic regression model
| Outcome Variable | AKI Definition | Level | Odds Ratio (95% CI) |
|
|
|---|---|---|---|---|---|
| Mortality | RIFLE | per 1 class | 4.5 (3.6 to 5.6) | <0.001 | 0.80 (0.75 to 0.85) |
| AKIN | per 1 stage | 5.3 (4.3 to 6.6) | <0.001 | 0.82 (0.77 to 0.87) | |
| Prolonged intubation (alive) | RIFLE | per 1 class | 3.3 (2.8 to 3.8) | <0.001 | 0.66 (0.64 to 0.69) |
| AKIN | per 1 stage | 3.3 (2.8 to 3.8) | <0.001 | 0.67 (0.64 to 0.69) | |
| ICU length of stay (alive), hours | RIFLE | per 1 class | 61 (54 to 68) | <0.001 | |
| AKIN | per 1 stage | 59 (53 to 66) | <0.001 | ||
| Hospital length of stay (alive), days | RIFLE | per 1 class | 4.3 (3.9 to 4.8) | <0.001 | |
| AKIN | per 1 stage | 4.1 (3.7 to 4.6) | <0.001 | ||
Outcomes of patients who require postoperative renal replacement therapy
| AKIN stage | No-RRT | RRT |
|
|---|---|---|---|
| 4,740 | 96 | ||
| Mortality, n (%) | 46 (1.0) | 43 (44.8) | <0.001 |
| Prolonged intubation (alive), n (%) | 419 (8.9) | 41 (77.4) | <0.001 |
| ICU length of stay (alive), hours | 25 (22 to 48) | 351 (163 to 517) | <0.001 |
| Hospital length of stay (alive), days | 6 (5 to 8) | 26 (18 to 40) | <0.001 |
Data are presented as median (interquartile range) if not otherwise stated.
Comparison of outcomes and baseline variables in patients detected as AKI by AKIN but not by RIFLE or not by AKIN but by RIFLE
| No-AKI | Group 1 | Group 2 | AKI |
|
| |
|---|---|---|---|---|---|---|
| 3452 | 466 | 112 | 582 | |||
| Mortality, (%) | 18 (0.5) | 6 (1.3) | 1 (0.9) | 15 (2.6) | 0.05 | 0.6 |
| Prolonged intubation (alive), n (%) | 191 (5.6) | 56 (12.2) | 20 (18.0) | 116 (20.5) | <0.001 | <0.001 |
| ICU length of stay (alive), hours | 24 (21 to 44) | 27 (22 to 60) | 43 (23 to 91) | 46 (23 to 94) | <0.001 | 0.004 |
| Hospital length of stay (alive), days | 6 (5 to 7) | 7 (6 to 9) | 7 (6 to 9) | 8 (6 to 11) | <0.0001 | 0.006 |
| Age, years | 62.5 ± 14.4 | 67.9 ± 13.8 | 65.1 ± 12.8 | - | <0.001 | 0.09 |
| LVEF, % | 60 ± 12 | 57 ± 13 | 55 ± 14 | - | <0.001 | <0.001 |
| Baseline serum creatinine, mg/dL | 1.09 ± 0.24 | 1.35 ± 0.37 | 0.86 ± 0.19 | - | <0.001 | <0.001 |
| Prior cardiac surgery, n (%) | 396 (11) | 84 (18) | 27 (24) | - | <0.001 | <0.001 |
Data are presented as median (interquartile range) or mean ± SD if not otherwise stated.
Patients with acute kidney injury (AKI) according to serum creatinine changes between baseline and first postoperative day (POD)
| RIFLE | AKIN | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Creatinine change between baseline and POD 1 | Entire cohort ( | No-AKI | class R | class I | class F | No-AKI | stage 1 | stage 2 | stage 3 |
| Increase, n (%) | 1,090 (22) | 422 (39) | 122 (11) | 23 (2) | 487 (45) | 32 (3) | 56 (5) | ||
| No change, n (%) | 955 (20) | 134 (14) | 25 (2.6) | 4 (0.4) | 165 (17) | 10 (1) | 5 (0.5) | ||
| Decrease, n (%) | 2,791 (58) | 159 (6) | 22 (0.8) | 4 (0.2) | 489 (18) | 15 (0.5) | 13 (0.5) | ||
| Total, n (%) | 4,836 (100) | 3,921 | 715 | 169 | 31 | 3,563 | 1,142 | 57 | 74 |